Pay in 4 interest-free payments of $5.96 Learn more
Ships within 48 hours · Estimated delivery Aug 7 - Aug 12
CJC-1295 (NO DAC) + Ipamorelin Blend Peptide Research Applications & Key Findings Growth Hormone Secretion Research Pituitary Function Studies Extensive research has examined the growth hormone secretagogue properties of the CJC-1295 + Ipamorelin combination across multiple species: Dose-dependent GH release demonstrated in rat anterior pituitary cell cultures with picomolar to micromolar peptide concentrations 2- to 10-fold increases in plasma growth hormone levels sustained for 6 days in human subjects following single CJC-1295 dose Preserved pulsatile secretion with ipamorelin addition, preventing continuous non-physiological stimulation Selective action on growth hormone release without affecting prolactin, ACTH, cortisol, FSH, or TSH levels Human trials with healthy subjects aged 21-61 years demonstrated sustained, dose-dependent increases in growth hormone and IGF-1 levels that were safe and well-tolerated at doses of 30-60 mcg/kg
Gastrointestinal side effects were the most commonly reported adverse events and decreased with continued dosing
The weight loss caused by Contrave may not benefit people who are pregnant and have the potential to harm the fetus
Medication can cause them to shrink from blocking the production and secretion of estrogen
Study type: randomized controlled trial
For patients who need to lose weight as part of managing metabolic diseases like type 2 diabetes or obesity, Mounjaros efficacy and safety profile make it the stronger option
US$ 25.81
US$ 26.17
US$ 21.16
US$ 23.76
US$ 22.58
US$ 27.33
US$ 22.07
US$ 27.22
US$ 26.76
